Capital Resource Partners provided $5m in mezzanine debt while Bridge Bank a $5m revolving line of credit.
Funds will be used to leverage the Northridge, Ca.-based Gamma Medica-Ideas‘ digital SPECT, PET and CT technologies into clinical imaging markets. The company’s initial product, LumaGEM, is focused on significantly improving the diagnosis of cancers in women with dense breast tissue.
Dr. Bradley E Patt, Ph.D., company’s co-founder, President and Chief Executive Officer, was reported to say: “We are ready today to demonstrate the strength of the technology platform with our product that we expect will have a huge impact in improving breast cancer diagnosis. We are now aggressively marketing our FDA cleared LumaGEM product for molecular breast imaging”.